| Fluorodesoxyglucose uptake in the remaining adrenal glands during the follow-up of patients with adrenocortical carcinoma: do not consider it as malignancy. | |
| | |
MedLine Citation:
|
PMID: 20921280 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To make the specificity of fluorodesoxyglucose ((18)FDG) positron emission tomography (PET) precise, in the follow-up of patients with adrenal cancer. DESIGN: This single centre retrospective study assessed the frequency and outcome of (18)FDG uptake in the remaining adrenal glands after adrenalectomy for adrenocortical carcinoma (ACC) or malignant phaeochromocytoma (PH). RESULTS: Two hundred and ten (18)FDG PET scans in 62 ACC patients, all under 1,ortho-1,para'-dichloro-diphenyl-dichloro-ethane (o,p'-DDD) treatment, and 30 (18)FDG PET scans in 8 PH patients were reviewed. Abnormal (18)FDG uptake in the remaining adrenal glands was found in 19 (8%) (18)FDG PET scans, in 10 (16%) ACC patients and in none of the PH patients. (18)FDG uptake was found in 4% of the patients before the onset of o,p'-DDD, in 29% of the patients 0-6 months after the onset of o,p'-DDD (P=0.05), in 26% of the patients 6-12 months (P=0.072) after the onset of o,p'-DDD and in 14% of the patients 12-24 months after the onset of o,p'-DDD. It was never found later than 24 months after the onset of o,p'-DDD. Adrenal glands with (18)FDG uptake were normal on computed tomography scans with i.v. contrast agent in all cases. (18)FDG uptake in the remaining adrenal glands decreased and disappeared on subsequent FDG PET imaging in eight of the patients with follow-up available. CONCLUSIONS: (18)FDG uptake in the remaining adrenal glands occurred in 14-29% of the patients followed for ACC within 24 months after adrenalectomy and onset of o,p'-DDD. This uptake is transient and should not be considered as suspicious for malignancy. |
| | |
Authors:
|
S Leboulleux; D Deandreis; C Escourrou; A Al Ghuzlan; F Bidault; A Aupérin; J P Travagli; J Lumbroso; M Schlumberger; E Baudin |
Publication Detail:
|
Type: Case Reports; Journal Article Date: 2010-10-04 |
Journal Detail:
|
Title: European journal of endocrinology / European Federation of Endocrine Societies Volume: 164 ISSN: 1479-683X ISO Abbreviation: Eur. J. Endocrinol. Publication Date: 2011 Jan |
Date Detail:
|
Created Date: 2010-12-14 Completed Date: 2011-01-10 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9423848 Medline TA: Eur J Endocrinol Country: England |
Other Details:
|
Languages: eng Pagination: 89-94 Citation Subset: IM |
Affiliation:
|
Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy, University Paris Sud, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France. leboulleux@igr.fr |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenal Cortex Neoplasms
/
metabolism,
radionuclide imaging*,
surgery Adrenal Glands / metabolism*, radionuclide imaging* Adrenalectomy* Adrenocortical Carcinoma / metabolism, radionuclide imaging*, surgery Adult Aged Female Fluorodeoxyglucose F18 / diagnostic use*, metabolism Follow-Up Studies Humans Male Middle Aged Pheochromocytoma / metabolism, radionuclide imaging*, surgery Positron-Emission Tomography* / methods Radiopharmaceuticals / diagnostic use Retrospective Studies Sensitivity and Specificity Time Factors |
| Chemical | |
Reg. No./Substance:
|
0/Radiopharmaceuticals; 63503-12-8/Fluorodeoxyglucose F18 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: How the adoption of impression management goals alters impression formation.
Next Document: The V?14 invariant natural killer T cell TCR forces microbial glycolipids and CD1d into a conserved ...